Selected article for: "amino acid and cross infection protection"
Author: Chunyun Sun; Long Chen; Ji Yang; Chunxia Luo; Yanjing Zhang; Jing Li; Jiahui Yang; Jie Zhang; Liangzhi Xie
Title: SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development
  • Document date: 2020_2_20
    • ID: nhq0oq8y_36
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.16.951723 doi: bioRxiv preprint cell receptors to initiate infection. Both SARS-CoV and SARS-CoV viruses use human ACE2 for cell entry 10 . Due to the nature of RNA virus' rapid mutation rates, changes in the S-protein's amino acid sequence, especially in the RBD's receptor binding motif, could have significant impact on virus infectivity.....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.16.951723 doi: bioRxiv preprint cell receptors to initiate infection. Both SARS-CoV and SARS-CoV viruses use human ACE2 for cell entry 10 . Due to the nature of RNA virus' rapid mutation rates, changes in the S-protein's amino acid sequence, especially in the RBD's receptor binding motif, could have significant impact on virus infectivity, pathogenicity, transmissibility, and cross-protection from previous coronavirus infection, as well as therapeutic antibody and prophylactic vaccine development. Hence, understanding the differences between SARS-CoV and SARS-CoV-2 and their implications may offer significant scientific and practical value.

    Search related documents:
    Co phrase search for related documents
    • amino acid and cell entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • amino acid and coronavirus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • amino acid and cross protection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • amino acid and infection initiate: 1, 2, 3
    • amino acid and prophylactic vaccine: 1, 2, 3, 4, 5
    • amino acid and rapid mutation: 1, 2, 3
    • amino acid and rapid mutation rate: 1
    • amino acid and RBD receptor bind motif: 1
    • amino acid and receptor bind motif: 1
    • amino acid and RNA virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • amino acid sequence and bind motif: 1
    • amino acid sequence and cell entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • amino acid sequence and coronavirus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • amino acid sequence and cross protection: 1, 2, 3
    • amino acid sequence and infection initiate: 1
    • amino acid sequence and prophylactic vaccine: 1
    • amino acid sequence and RNA virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • bind motif and cell entry: 1, 2, 3, 4
    • bind motif and RBD receptor bind motif: 1, 2